Quarterly report pursuant to Section 13 or 15(d)

Share-based Payments

v3.7.0.1
Share-based Payments
6 Months Ended
Jun. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Share-based Payments

Note 10 - Share-based Payments

 

On January 23, 2014, upon effectiveness of the registration statement filed with the SEC, the Company adopted the 2013 Stock Incentive Plan (the “Plan”) which provides for the issuance of up to 400,000 shares. The purpose of the Plan is to provide additional incentive to those officers, employees, consultants and non-employee directors of the Company and its parents, subsidiaries and affiliates whose contributions are essential to the growth and success of the Company’s business.

 

On January 9, 2015, the Board of Directors of the Company approved, upon recommendation from the Compensation Committee of the Board, by unanimous written consent the Amended and Restated 2013 Incentive Stock and Award Plan (the “Amended Plan”), which increased the number of authorized shares of common stock subject to the Plan to 800,000 shares.

 

On September 30, 2016, the Board of Directors increased the number of authorized shares of common stock subject to the Amended Plan to 830,000 shares. As of June 30, 2017, under the 2013 Amended Plan, grants of restricted stock and options to purchase 268,166 shares of common stock have been issued and are unvested or unexercised and 3,292 shares of common stock remain available for grants.

 

The Amended Plan may be administered by the board or a board-appointed committee. Eligible recipients of option awards are employees, officers, consultants or directors (including non-employee directors) of the Company or of any parent, subsidiary or affiliate of the Company. The board has the authority to grant to any eligible recipient any options, restricted stock or other awards valued in whole or in part by reference to, or otherwise based on, the Company’s common stock.

 

Qualified option holders may exercise their options at their discretion. Each option granted may be exchanged for a prescribed number of shares of common stock.

 

The Company did not issue any options or warrants under the above plan during the three and six months ended June 30, 2017.

 

The following table summarizes the option activities for the six months ended June 30, 2017:

 

                Weighted        
                Average        
          Weighted     Remaining     Aggregate  
    Number of     Average     Contractual     Intrinsic  
    Shares     Exercise Price     Term (years)     Value  
Balance at December 31, 2016     259,000     $ 4.23       3.05     $ 20,100  
Granted     -       -       -       -  
Exercised     -       -       -       -  
Forfeited     -       -       -       -  
Canceled/Expired     -       -       -       -  
Balance at June 30, 2017     259,000     $ 4.23       2.55     $ 600  
Exercisable as of June 30, 2017     241,667     $ 4.30       2.44     $ 600  

 

The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the closing stock price of $1.25 for our common shares on June 30, 2017.

 

A summary of the Company’s non-vested shares as of June 30, 2017 and the changes during the period then ended are as follows:

 

          Weighted  
          Average Grant  
Non-Vested Shares   Shares     Date Fair Value  
Non-vested at January 1, 2017     19,834     $ 2.36  
Granted     -       -  
Vested     (2,500 )     1.05  
Forfeited     -       -  
Non-vested at June 30, 2017     17,334     $ 2.36  

 

Unrecognized compensation cost related to non-vested employee stock options totaled $23,167 as of June 30, 2017. The cost is to be recognized over a weighted average period of 1.13 years.

 

During the three and six months ended June 30, 2017, the Company incurred stock option expenses totaling $7,275 and $12,367. No stock option expenses were incurred in the three and six months ended June 30, 2016.

 

During the six months ended June 30, 2017, the Company issued 894,750 warrants in conjunction with a public offering of its common shares in January 2017 and an additional 796,620 warrants in connection a private placement of its common shares in March 2017. All warrants carry a five-year expiration term. The table below summarizes the warrant activity for the six months ended June 30, 2017:

 

                Weighted  
          Weighted     Average  
          Average     Remaining  
      Number of
Warrants
      Exercise Price       Contractual
Term (years)
 
Balance at December 31, 2016     -     $ -       -  
Granted     1,691,370       1.88       -  
Exercised     (200,800 )     1.50       -  
Forfeited     -       -       -  
Canceled/Expired     -       -       -  
Balance at June 30, 2017     1,490,570     $ 1.73       4.65  
Exercisable as of June 30, 2017     693,950     $ 1.47       4.54